Before revision:  Patients with acute respiratory distress who were taking \alpha_1-AR antagonists for other conditions had a 35\% reduced risk of requiring ventilation , and a 56\% reduced risk of ventilation and death, compared to non-users (adjusted OR = 0.41 , 95\% CI 0.17-0.81, p = 0.01).
After revision:  Patients with acute respiratory distress who were taking \alpha_1-AR antagonists for other conditions had a 35\% reduced risk of requiring ventilation (by 35\% and 16\%, respectively), and a reduced risk of ventilation and death, compared to non-users (adjusted OR = 0.41 , 95\% CI 0.17-0.81, p = 0.01).